With over 5.7 million Edwards Lifesciences Corp (EW) shares trading Monday and a closing price of $64.60 on the day, the dollar volume was approximately $368.4 million. The shares have shown a negative half year performance of -27.35% and its price on 11/13/23 gained nearly 0.61%. Currently, there are 608.30M common shares owned by the public and among those 597.03M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 32 analysts who have offered their price forecasts for EW have a consensus price objective of $80.47. The analysts have set the share’s price value over the next 12 months at a high of $102.00 and a low of $63.00. The average price target is 19.72% above its recent price level and a downside to the estimated low will see the stock lose -2.54% over that period. But an upside of 36.67% will see the stock hit the forecast high price target while median target price for the stock is $80.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 206 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 90 of these insider trades were purchases, accounting for 1,113,290 shares. Insider sales of the common stock occurred on 116 occasions, with total insider shares sold totaling 943,007 shares.
Shares of Edwards Lifesciences Corp (NYSE: EW) opened at $65.83, up $1.62 from a prior closing price of $64.21. However, the script later moved the day high at 66.22, up 0.61%. The company’s stock has a 5-day price change of -3.73% and -19.11% over the past three months. EW shares are trading -13.42% year to date (YTD), with the 12-month market performance down to -10.96% lower. It has a 12-month low price of $60.57 and touched a high of $94.87 over the same period. EW has an average intraday trading volume of 4.03 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.11%, -7.77%, and -19.52% respectively.
Institutional ownership of Edwards Lifesciences Corp (NYSE: EW) shares accounts for 85.83% of the company’s 608.30M shares outstanding.
It has a market capitalization of $39.18B and a beta (3y monthly) value of 1.01. The stock’s trailing 12-month PE ratio is 27.62, while the earnings-per-share (ttm) stands at $2.34. The company has a PEG of 3.15 and a Quick Ratio of 2.45 with the debt-to-equity ratio at 0.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.55% over the week and 3.01% over the month.
Analysts forecast that Edwards Lifesciences Corp (EW) will achieve an EPS of $0.64 for the current quarter, $0.67 for the next quarter and $2.81 for 2024. The lowest estimate earnings-per-share for the quarter is $0.63 while analysts give the company a high EPS estimate of $0.66. Comparatively, EPS for the current quarter was $0.64 a year ago. Earnings per share for the fiscal year are expected to increase by 1.21%, and 12.06% over the next financial year. EPS should shrink at an annualized rate of 8.78% over the next five years, compared to 22.06% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 32 brokerage firm advisors rate Edwards Lifesciences Corp (EW) as a “Strong Buy” at a consensus score of 1.97. Specifically, 15 Wall Street analysts polled rate the stock as a buy, while 12 of the 32 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the EW, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on September 26, 2023, with the firm’s price target at $90.
